GlassScriptPhysician profile
Neha Maheshwari
NPI 1033212915
$6,288.56
in general payments reported to CMS, 2019-2025
44 companies · $926 in 2025
The $926 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $246 · 2020: $678 · 2021: $916 · 2022: $1,101 · 2023: $1,019 · 2024: $1,403 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,327 · Entertainment: $20.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.33 |
| Entertainment | $20.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,290.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,146.70 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $574.47 | 2019-2025 | Xifaxan, Relistor |
| Novo Nordisk INC | $526.95 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $350.94 | 2020-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $306.27 | 2020-2025 | Octrode, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.10 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $222.15 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $214.55 | 2020-2024 | Repatha, Otezla, Evenity |
| Allergan, INC. | $203.35 | 2019-2022 | |
| Boston Scientific Corporation | $126.06 | 2019-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $104.42 | 2019-2024 | Gardasil, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.33 | 2025 | Caplyta |
| Pfizer INC. | $74.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.75 | 2021-2023 | Trintellix |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $58.37 | 2022-2023 | Nexplanon |
| Astellas Pharma US INC | $51.37 | 2025 | Veozah |
| Exact Sciences Corporation | $49.37 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $49.20 | 2024-2025 | |
| Angiodynamics, INC. | $46.30 | 2025 | Venacure 1470 Pro |
| Genentech USA, INC. | $39.96 | 2020 | |
| Sanofi Pasteur INC. | $39.55 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $35.75 | 2025 | Zoryve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.48 | 2020 | |
| Almatica Pharma LLC | $22.97 | 2024 | Loreev Xr |
| Fidia Pharma USA INC. | $20.76 | 2020 | |
| Optos, INC. | $20.65 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Edwards Lifesciences Corporation | $20.12 | 2020 | |
| Phathom Pharmaceuticals, INC. | $19.16 | 2024 | Voquezna |
| Nevro Corp. | $18.85 | 2020 | |
| Depuy Synthes Sales INC. | $18.71 | 2024 | Monovisc |
| Biotronik INC. | $18.38 | 2021 | |
| Axonics, INC. | $17.74 | 2024 | Axonics |
| Alfasigma USA, INC. | $17.50 | 2020 | |
| Medtronic USA, INC. | $17.02 | 2020 | |
| Lundbeck LLC | $16.91 | 2025 | Vyepti |
| Gilead Sciences, INC. | $16.38 | 2025 | |
| Baxter Healthcare | $16.33 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Phadia US INC. | $15.84 | 2025 | Immunocap |
| Novartis Pharmaceuticals Corporation | $15.52 | 2019 | |
| Eisai INC. | $15.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.15 | 2022 | |
| Stryker Corporation | $13.74 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Maheshwari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.